New board appointment at Orexigen
This article was originally published in Scrip
Orexigen Therapeutics, a US biopharmaceutical company focused on the treatment of obesity, has elected Dr Peter Honig to its board of directors. Dr Honig has more than 20 years' clinical and regulatory policy experience from past roles with Merck & Co and the US FDA. Most recently, he was senior vice-president of worldwide regulatory affairs and product safety at Merck and co-chair of Merck's late development review committee, overseeing the company's late-stage pipeline.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.